Fig. 2: Treatment discontinuation due to any reason. | Translational Psychiatry

Fig. 2: Treatment discontinuation due to any reason.

From: A meta-analysis of effectiveness of real-world studies of antipsychotics in schizophrenia: Are the results consistent with the findings of randomized controlled trials?

Fig. 2

Results of individual studies included in the meta-analysis along with pooled meta-analytic estimates based on random effect model. The figure provides the results for the 25 individual pair-wise comparisons. The results of pair-wise comparison are arranged in alphabetical order. A Results for the first set of comparisons (n = 15); B Results for the second set of comparisons (n = 10). Relative Risk of discontinuation for the first and second APs is indicated as a value of <1 or >1, depending on whether the first or the second AP in the pair has superior or inferior efficacy, respectively. For example, in the clozapine vs. haloperidol pairwise comparison, clozapine was found to be superior over haloperidol as our pooled estimate was 0.33, while in the amisulpride vs. olanzapine comparison, olanzapine showed superiority over amisulpride with an RR of 1.45. For the graphical illustration, the UCL value (5.556) was truncated at 4 in the case of the haloperidol oral–olanzapine oral pair-wise comparison from the Jari Tiihonen (2006) study. RR relative risk, LCL lower confidence limit, UCL upper confidence limit. Blue The results of individual real-world studies, Red Pooled estimates of current meta-analysis.

Back to article page